.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
Complimentary print subscription for home or office delivery
In-person and virtual events just for HCPs
Lively expert panel discussions featuring peer-to-peer exchanges
Subscribe to our eNewsletter for breaking news and curated content

SpecialtySee All >

Breast Cancer
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Management of Chemotherapy-Induced Nausea and Vomiting (CINV)

EP. 1: Challenges in the Treatment of CINV

July 17th 2017

EP. 2: Types of CINV

July 17th 2017

EP. 3: Classification of Emetogenicity of Chemotherapeutic Agents

July 17th 2017

EP. 4: Multidisciplinary Approach to Treating CINV

July 17th 2017

EP. 5: Patient Risk Factors in CINV

July 17th 2017

EP. 6: Patient Education Materials for CINV

July 17th 2017

EP. 7: Treating CINV Due to Immunotherapy and Targeted Therapy

July 17th 2017

EP. 8: Role of 5-HT3 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 9: Role of NK1 Receptor Antagonists in Treating CINV

July 17th 2017

EP. 10: 5-HT3/NK1 Receptor Antagonist Combinations for CINV

July 17th 2017

EP. 11: Use of Olanzapine in CINV

July 17th 2017

EP. 12: Use of Dexamethasone in CINV

July 17th 2017

EP. 13: Unmet Needs in CINV

July 17th 2017